Clinical Trials Logo

Citation(s)

A Phase I Dose Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy With Biomarker Analysis in Patients With HER2-Overexpressing Breast Cancer

Details for clinical trial NCT00544804